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Abstract
Background: Self-renewing, chemoresistant breast cancer stem cells are believed to contribute significantly to
cancer invasion, migration and patient relapse. Therefore, the identification of signaling pathways that regulate the
acquisition of stem-like qualities is an important step towards understanding why patients relapse and towards
development of novel therapeutics that specifically target cancer stem cell vulnerabilities. Recent studies identified
a role for the aryl hydrocarbon receptor (AHR), an environmental carcinogen receptor implicated in cancer
initiation, in normal tissue-specific stem cell self-renewal. These studies inspired the hypothesis that the AHR plays a
role in the acquisition of cancer stem cell-like qualities.
Results: To test this hypothesis, AHR activity in Hs578T triple negative and SUM149 inflammatory breast cancer cells
were modulated with AHR ligands, shRNA or AHR-specific inhibitors, and phenotypic, genomic and functional stem
cell-associated characteristics were evaluated. The data demonstrate that (1) ALDHhigh cells express elevated levels
of Ahr and Cyp1b1 and Cyp1a1, AHR-driven genes, (2) AHR knockdown reduces ALDH activity by 80 %, (3) AHR
hyper-activation with several ligands, including environmental ligands, significantly increases ALDH1 activity,
expression of stem cell- and invasion/migration-associated genes, and accelerates cell migration, (4) a significant
correlation between Ahr or Cyp1b1 expression (as a surrogate marker for AHR activity) and expression of stem
cell- and invasion/migration-associated gene sets is seen with genomic data obtained from 79 human breast
cancer cell lines and over 1,850 primary human breast cancers, (5) the AHR interacts directly with Sox2, a master
regulator of self-renewal; AHR ligands increase this interaction and nuclear SOX2 translocation, (6) AHR knockdown
inhibits tumorsphere formation in low adherence conditions, (7) AHR inhibition blocks the rapid migration of
ALDHhigh cells and reduces ALDHhigh cell chemoresistance, (8) ALDHhigh cells are highly efficient at initiating tumors
in orthotopic xenografts, and (9) AHR knockdown inhibits tumor initiation and reduces tumor Aldh1a1, Sox2, and
Cyp1b1 expression in vivo.
Conclusions: These data suggest that the AHR plays an important role in development of cells with cancer stem
cell-like qualities and that environmental AHR ligands may exacerbate breast cancer by enhancing expression of
these properties.
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Background
Given the emerging evidence that common environmental
carcinogens play a significant role in cancer [1], increased
attention has been paid to molecular mechanisms through
which pollutants affect tumor formation, invasion and/or
progression [2–4]. Historically, most studies on environ-
mental chemical carcinogenesis centered on the ability of
genotoxic chemicals to damage DNA, induce mutations,
and initiate cancers [5–7]. However, recent data suggest
alternative, non-genotoxic pathways involving cellular re-
ceptors that can be activated by environmental ligands.
One such receptor is the aryl hydrocarbon receptor
(AHR). The AHR is the only ligand-activated member of
the Per-ARNT-Sim (bHLH/PAS) family of transcription
factors, all of which play important roles as environmen-
tal- and physiological stress-sensing proteins [8]. The
AHR has been best studied for its ability to be activated
by dioxins, polychlorinated biphenyls, and polycyclic aro-
matic hydrocarbons [9], all of which are high priority che-
micals on the U.S. Agency for Toxic Substances and
Disease Registry list of pollutants of greatest concern to
human health (http://www.atsdr.cdc.gov/SPL/resources).
Ligand-bound AHR induces P450 enzymes such as
CYP1B1 and CYP1A1, which are capable of generating
mutagenic intermediates. However, more recent work
suggests that the AHR, which is expressed at aberrantly
high levels and is chronically active in several cancers,
plays an ongoing role in tumor progression by enhancing
tumor invasion and migration [10–15]. The contribution
of the AHR to the later stages of cancer may be mediated
by non-genotoxic endogenous ligands, which chronically
drive AHR transcriptional activity [16, 17]. Here, it is pos-
tulated that environmental ligands mimic this effect and
drive cancer progression, at least in part, by increasing the
development and/or function of cells exhibiting cancer
stem-like cell (CSLC) properties.
Recent evidence suggests that invasion and eventual
metastasis leading to patient death is mediated, to a dis-
proportionate extent, by chemoresistant, long-lived can-
cer stem cells, sometimes referred to as tumor-initiating
cells [18–25]. Breast cancer stem cells can be defined by
(1) expression of genes associated with ‘normal’ tissue
stem cells (e.g. Notch1,2, Sox2, Pou5F1/Oct4) and with
invasion and migration (e.g. Twist1,2,Vim, Snai1, Snai2)
[26–30]; (2) formation of spheroid colonies in ultra-low
adherence cultures [31]; (3) elevated levels of aldehyde
dehydrogenases (ALDH), enzymes associated with che-
moresistance, high histological tumor grade, and poor
prognoses [19, 21, 32]; (4) the propensity to self-renew
while spawning progenitor cells [31, 33]; and (5) an in-
creased tumor initiation capacity in xenografts [31, 33].
Here, we operationally define ‘breast cancer stem-like
cells’ (BCSLC) as tumor cells robustly expressing the five
aforementioned characteristics in a continuum of ‘stem-
ness’ in which some cells are more stem-like than others
at any given time. Clearly, identifying factors responsible
for the development of cells with cancer stem cell qual-
ities is an important step towards understanding why
many patients relapse, even several years after remission.
The AHR plays an important role in tissue-specific em-
bryonic development, hematopoietic stem cell self-
renewal, pluripotent stem cell and neural stem cell differ-
entiation, and megakaryocyte/erythroid stem cell growth
[34–40]. Here, complementing parameters of ‘stem-ness’,
including ALDH enzyme activity, stem cell-, invasion-
and migration-associated gene expression, tumorsphere
formation, migration rate, chemoresistance, and tumor
formation at limiting concentrations in xenografts were
assessed to test the hypothesis that the AHR similarly
influences development and function of BCSLCs. The po-
tential for the AHR to directly interact with the Sox2 gene,
a master regulator of normal tissue-specific stem cell self-
renewal and differentiation, was of particular interest.
These studies were performed primarily with ER−/PR
−/Her2− triple negative breast cancer (TNBC) cell lines:
Hs578T, derived from a carcinomosarcoma, and SUM149,
derived from an inflammatory breast cancer (IBC). TNBC
lines were selected for these studies primarily because no
effective targeted therapeutic is yet available for this class
of breast cancers and because we wanted to evaluate AHR
signaling in the absence of its well-established interactions
with the estrogen receptor [41]. Results in those lines were
compared with genomic outcomes in 79 breast cancer cell
lines and more than 1,850 primary cancers. Our results
show that the AHR is involved in the control of pheno-
typic, genomic, and functional cancer stem cell markers in
ER−/PR−/Her2− cells, strongly implicating an important
role for the AHR in acquisition of stem cell-like qualities,
encouraging development of AHR-targeted therapeutics,
and raising the possibility that environmental AHR ligands
may drive BCSLC development or activity.
Results
AHR expression is elevated in ALDH1high TNBCs
We have previously published data demonstrating ele-
vated expression of transcriptionally (‘constitutively’)
active AHR in human breast cancer cell lines [10, 15,
42, 43]. The expression of nuclear AHR in ER−/PR−/Her2−
human breast cancer-derived Hs578T cells and in inflam-
matory ER−/PR−/Her2− breast cancer-derived SUM149
cells (Additional file 1: Figure S1A) was consistent with
these reports. Furthermore, a predominance of nuclear
AHR in primary human breast cancers (Additional file 1:
Figure S1B, middle and bottom panels), but not in normal
breast tissue (Additional file 1: Figure S1B, top panel), sup-
ports the conclusion that the AHR is constitutively active
in primary cancers as well. Importantly, non-epithelial cells
did not express AHR, normal epithelial cells in ducts had a
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low level of AHR staining, similar to our previous findings
in rats [44], and all AHR staining seen in normal epithelial
cells was cytoplasmic, indicating inactive AHR. Note that
the stains presented here are representative of similar stain-
ing observed in 50 human breast cancer samples fixed on a
tissue microarray.
Work from several laboratories indicates a role for the
AHR in tissue-specific stem cell development [34–38],
suggesting a general role for the AHR in stem cell biology.
We and others have demonstrated that the AHR is highly
expressed and constitutively active in breast cancers
and that its activity correlates with tumor aggressive-
ness [10, 44–47]. Since cancer stem cells contribute
to tumor progression, we postulated that the AHR
plays a role in the development of breast cancer cells
with stem cell-like characteristics (BCSLC).
Several investigators have shown that CD44+/CD24−
cell staining is not an entirely consistent indicator of
tumor initiating ability in ER−/PR−/Her2− breast cancer
cells due to over-staining of TNBCs [23, 48–51]. Over-
expression or non-specific staining for these prototypic
cancer stem cell markers also precluded their use in our
studies (data not shown). Therefore, ALDH activity,
which appears to be a more selective functional marker
for TNBC stem-like cells [19, 23, 52, 53], was used here
for marking of and enriching for cancer stem-like cells.
A fluorescence-based ALDH1 enzyme activity assay
[19, 20, 23, 52, 53] was used to quantify ALDH1 activity
in TNBC Hs578T cells, which express relatively high
levels of transcriptionally active AHR [15]. Cells were
sorted by flow cytometry into ALDH1high and ALDH1low
subsets. Approximately 5 % of Hs578T cells expressed
high levels of ALDH1 activity (ALDHhigh; Fig. 1a, right
panel), a result consistent with previous studies of BCSLCs
[20]. To determine if the Ahr and an AHR target gene,
Cyp1b1, are more highly represented in ALDHhigh cells,
Ahr and Cyp1b1 mRNAs were quantified by RT-qPCR. Ahr
and Cyp1b1 mRNAs were significantly higher in ALDHhigh
cells than ALDHlow cells (P <0.05–0.005; Fig. 1b).
To determine if elevated Ahr and Cyp1b1 expression
in ALDH1high cells reflects a role for the AHR in main-
taining stem cell properties and if environmental AHR
ligands have the potential to increase these properties in
TNBCs, AHR expression or activity was modulated with
a doxycycline (dox)-inducible Ahr-specific shRNA (shAhr),
AHR inhibitors (CH223191 and CB7993113) [42, 54, 55],
or four AHR agonists: (1) 6-formylindolo[3,2-b]carbazole
(FICZ), a high affinity AHR ligand, tryptophan photo-
metabolite, and potential endogenous ligand [56]; (2)
β-naphthoflavone (β-NF), a flavone with moderate affinity
for the AHR; (3) 2,3,7,8-tetrachlorodibenzo(p)dioxin
(TCDD), a high affinity, persistent environmental AHR
ligand and ‘gold standard’ AHR ligand; or (4) 7,12
dimethylbenzanthracene (DMBA), a readily metabolizable
polycyclic aromatic hydrocarbon.
Dox-induced shAhr or the AHR-specific inhibitor
CH223191 significantly reduced (P <0.01–0.0001) Ahr ex-
pression and AHR-dependent (pGudLuc) reporter activity,
respectively (Fig. 2a), significantly decreased (P <0.05–
0.0005) the percentage of ALDHhigh cells by over 80 %
(Fig. 2b, c), and reduced overall ALDH1 activity in the en-
tire Hs578T population (Fig. 2d), suggesting that ‘constitu-
tively active’ (endogenous ligand-activated) AHR maintains
baseline ALDH1 levels. Similar data were obtained with
our recently described AHR inhibitor, CB7993113 [42]
(not shown). Conversely, FICZ, β-NF, TCDD, or DMBA
significantly increased the percentage of ALDH1high cells
and ALDH1 activity in the entire Hs578T population
Fig. 1 Ahr and Cyp1b1 expression is increased in ALDH1high Hs578T cells. (a) ER−/PR−/HER2− Hs578T cells were stained with ALDEFLUOR™ in the
presence or absence of diethylaminobenzaldehyde (DEAB), a specific ALDH inhibitor, and ALDH activity (production of fluorescent substrate) was
quantified by flow cytometry. Regions were set using dot plots from DEAB-treated cells. Data are representative of 24 experiments. (b) Ahr and
Cyp1b1 mRNA expression in sorted ALDHhigh and ALDHlow cells was quantified by RT-qPCR. Data from three independent experiments were
analyzed using the Pfaffl method [103], normalized to the Gapdh signal, and presented as mean fold-change from ALDHlow ± standard
error. Asterisks indicate a significant increase in the mRNA fold-change, *P <0.05, **P <0.005
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(P <0.05–0.005; Fig. 2b,c, d). In all cases, AHR
agonist-induced increases were significantly inhibited
by CH223191 (P <0.05–0.001). Similar results were
obtained with immortalized but non-malignant triple
negative MCF-10F cells (Additional file 2: Figure S2)
and with ER+ luminal-type MCF7 cells [57] (data not
shown). These results suggest that AHR ligand-
induced ALDH up-regulation is likely generalizable to
different breast cancer subtypes.
Increasing AHR activity increases expression of BCSLC-
related genes
To determine if several stem cell-associated genes are reg-
ulated by the AHR, Hs578Tcells were treated for 48 hours
with vehicle or FICZ, stained with ALDEFLUORTM, and
sorted for ALDHhigh and ALDHlow cells. Consistent with
previous studies demonstrating BCSLC plasticity [58], pre-
sorting Hs578T ALDHhigh and ALDHlow cells prior to
treatment and culture for 48 hours was precluded by the
Fig. 2 AHR modulation alters ALDH1 activity in Hs578T cells. (a) Wildtype or doxycycline (dox)-inducible shAhr-transduced Hs578T cells were
transfected with CMV-green control plasmid and AHR-driven pGudLuc reporter and treated for 48 hours with 10 μM AHR inhibitor CH223191 or
with doxycycline (1.5 μg/mL) to induce the shAhr. Ahr mRNA was quantified by RT-qPCR and normalized to Gapdh mRNA expression. pGudLuc
activity was assayed by luminescence and normalized to CMV-green expression. Values were normalized to Ahr or pGudLuc levels in untreated
Hs578T cells. Data are presented as mean ± standard error. Left panel n = 6, middle panel n = 3, right panel n = 6. Asterisks indicate a significant
decrease in the mRNA fold-change or reporter activity, *P <0.01, **P <0.001, ***P <0.0001. (b) Representative flow cytometry plots of ALDEFLUOR™
staining of wildtype Hs578T cells or dox-inducible shAhr-transduced Hs578T cells treated for 48 hours are presented. Dox-inducible shAhr transduced
Hs578T cells were treated for 48 hours with dox. Hs578T wildtype cells were treated for 48 hours with vehicle, 10 μM CH223191, 1 μM β-NF, 0.5 μM
FICZ, 1 nM TCDD, or 1 μM DMBA. Regions representing ALDHhigh cells were drawn based on the signal generated in the presence of DEAB. (c) Hs578T
cells were treated as in (b) and assayed for the percentage of ALDHhigh cells. Data were normalized to results obtained with naïve cells (mean
baseline = 4.7 % ALDHhigh cells) and presented as mean fold-change from naive ± standard error. Number of experiments by condition:
shAHR-dox n = 10, shAHR + dox n = 10, DMSO n = 24, CH223191 n = 9, FICZ n = 16, FICZ + CH223191 n = 5, β-NF n = 5, β-NF + CH223191
n = 5, TCDD n = 10, TCDD + CH223191 n = 3, DMBA n = 10, and DMBA + CH223191 n = 4. Asterisks indicate a significant decrease in the
percentage of ALDHhigh cells, *P <0.05, **P <0.001, ***P <0.0005. A cross indicates a significant increase in ALDHhigh cells, +P <0.05, ++P <0.01,
+++P <0.005. (d) Depicted are flow cytometry dotplots of dox-inducible shAhr-transduced Hs578T cells without dox (red dots) versus with dox
(black dots), wildtype Hs578T cells treated with vehicle (red dots) versus CH223191 (black dots), or wildtype Hs578T cells treated with vehicle
(red dots) versus FICZ (black dots). Data are representative plots of independent experiments of the data presented in (c)
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tendency for sorted Hs578T subpopulations to revert to
the original distribution of ALDHhigh (~5 %) and ALDHlow
(~95 %) cells within 24 hours (data not shown).
As expected, vehicle-treated ALDHhigh cells produced
higher levels of Aldh1a1, Ahr, Cyp1b1, and Cyp1a1 than
vehicle-treated ALDHlow cells (P <0.005; Fig. 3a). Aldh3a1
mRNA, previously associated with AHR activity [59], was
not detected (>33 cycles) in either vehicle or AHR agonist
(FICZ or β-naphthoflavone)-treated Hs578T cells (data
not shown). ALDHhigh cells also expressed significantly
higher levels of seven of the eight stem cell-associated
genes studied (P <0.05–0.005) with Msi1 being the excep-
tion (Fig. 3a). As expected from the ALDH enzyme activ-
ity assay (Fig. 2), FICZ treatment increased Aldh1a1,
Cyp1b1, and Cyp1a1 expression in both ALDHlow and
ALDHhigh cells (P <0.05–0.01; Fig. 3b, c). Consistent with
previous studies, AHR ligand induced significantly higher
levels of Cyp1a1 than Cyp1b1 (P <0.05), while baseline
Cyp1b1 levels tended to be higher than Cyp1a1 levels [15].
FICZ also increased expression of seven of eight stem
cell-associated genes in both cell subsets (P <0.05–0.005),
again withMsi1 being the outlier (Fig. 3b, c). These results
support the hypothesis that constitutively active and/or
exogenous agonist-induced AHR up-regulates multiple
stem cell-associated genes. Several of these genes express
multiple consensus AHR response elements (Table 1), sug-
gesting that they may be directly regulated by the AHR.
Given the pivotal role for Sox2 in stem cell self-
renewal, BCSLC development and breast cancer out-
comes [27, 60–63], AHR/Sox2-specific ChIP assays were
performed to determine if the AHR directly interacts
with the Sox2 promoter. ChIP assays measuring AHR-
Cyp1b1 promoter binding served as positive controls
[15]. Indeed, there was a significant basal level of AHR
binding to both Cyp1b1 and Sox2 promoter fragments
(P <0.005; Fig. 4a), each of which contains several AHR
response elements within 500 bp of the PCR primer
binding sites (Table 1). AHR inhibition with CH223191
significantly decreased AHR-Sox2 and AHR-Cyp1b1
binding (P <0.05). AHR hyper-activation with FICZ sig-
nificantly increased AHR-Cyp1b1 and AHR-Sox2 binding
by approximately 3-fold and 2-fold, respectively (P <0.05).
The AHR-Sox2 increase was blocked with CH223191 treat-
ment (P <0.05; Fig. 4a). Furthermore, treatment of SUM149
cells or MCF-7 cells, which are known to express relatively
high SOX2 levels [64], with FICZ, TCDD, or β-NF consist-
ently increased nuclear SOX2 (Fig. 4b, c), a result consistent
with increased levels of transcriptionally active SOX2

































































































































































































































































































Fig. 3 AHR hyper-activation increases expression of stem cell-associated genes. Hs578T cells were treated with vehicle or 0.5 μM FICZ for 48 hours,
sorted into ALDHhigh and ALDHlow cell populations, and then assayed by RT-qPCR for the relative levels of the eight stem cell-associated genes
indicated. Gene expression was then normalized to Gapdh levels and fold-change from vehicle-treated ALDHlow or ALDHhigh cells was calculated.
Data from nine independent experiments are presented as the mean fold-change ± standard error for all genes except for Cyp1a1, in which six
independent experiments are presented. In all cases, statistical significance was determined with the Wilcoxon rank sum test to determine if the
distributions of results, relative to 1 as the standard (represented by the dotted line on each graph), are different between the comparison groups.
Asterisks indicate a significant increase in the mRNA fold-change, *P <0.05, **P <0.01, ***P <0.005. (a) Expression levels of stem cell-associated
genes were normalized to expression levels in vehicle-treated ALDHlow cells and the distribution of outcomes from vehicle-treated ALDHhigh
versus vehicle-treated ALDHlow cells compared. (b) Stem cell-associated gene expression levels were normalized to expression levels in vehicle-treated
ALDHlow cells and the distribution of outcomes from vehicle-treated ALDHlow versus FICZ-treated ALDHlow cells was compared. (c) Stem cell-associated
gene expression levels were normalized to expression levels in vehicle-treated ALDHhigh cells and the distribution of outcomes from vehicle-treated
ALDHhigh versus FICZ-treated ALDHhigh cells was compared
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following AHR hyper-activation. Finally, ectopic Sox2 ex-
pression significantly increased ALDH1 activity (P <0.005;
Fig. 4d). These data strongly suggest that the AHR directly
interacts with Sox2, a critical BCSLC-associated gene, which
in turn regulates ALDH1 expression, an enzyme associated
with chemoresistance [53].
Increasing AHR activity increases expression of migration-
and invasion-associated genes
BCSLCs are more invasive than the bulk tumor popula-
tion and have increased expression of migration- and
invasion-associated markers [21, 22, 28, 29, 53, 58, 65].
To determine if the increase in stem cell markers de-
scribed above correlates with markers of migration and
invasion, Hs578T cells were treated with vehicle or FICZ
for 48 hours, sorted for ALDHhigh and ALDHlow cells,
and evaluated for expression of seven genes associated
with increased tumor migration and/or invasion. As seen
for stem cell markers (Fig. 3), ALDHhigh cells expressed
significantly higher levels (P <0.005–0.0005) of Snai1,
Twist 1, Twist2, Tgfb1, and Vim than ALDHlow cells,
with Twist2 showing the greatest fold-change (Fig. 5a).
Although Snai2 and Fn1 tended to be higher in ALDHhigh
cells, neither was statistically significant in nine independ-
ent experiments. These data are consistent with the BCSLC
properties of ALDHhigh cells. AHR hyper-activation with
FICZ significantly (P <0.05–0.0005) increased Snai1,
Twist1, Twist2, and Vim in both ALDHhigh and ALDHlow
cells (Fig. 5b,c) and Tgfb1 was marginally increased in
FICZ-treated ALDHlow cells (Fig. 5c).
As a functional readout of migration, the effects of AHR
modulation on the ability of SUM149 cells to migrate in a
48 hour scratch-wound assay were determined. SUM149
cells were chosen for this experiment since, unlike
Hs578T cells, ALDHhigh SUM149 cells remained ALDH-
high in vitro for at least 96 hours, unless the AHR inhibitor,
CH223191 was added (Additional file 3: Figure S3A).
ALDHlow, SUM149 cells tended to revert to ALDHhigh
phenotype but this reversion was inhibited by CH223191
treatment (Additional file 3: Figure S3B). Similar results
describing the plasticity of stem-like cells have been previ-
ously reported [58].
As expected, vehicle-treated ALDHhigh cells ‘repaired’
the wound significantly faster than vehicle-treated
ALDHlow cells, as quantified by a decrease in exposed sur-
face area (Fig. 6; P <0.05 at 48 hours). Furthermore, wound
repair with both subpopulations was significantly inhibited
by CH223191 treatment (Fig. 6; P <0.05–0.0005). Similar
data were obtained with unsorted Hs578T and SUM149
cells and with another AHR inhibitor, CB7993113 (not
shown). No cell divisions were observed over this 48-hour
period as assessed by CFSE staining and analysis by flow
cytometry (not shown). In addition, both 0.5 μM FICZ and
1 nM TCDD significantly accelerated migration of un-
sorted, ALDHlow (not shown), and ALDHhigh SUM149
subsets (Additional file 4: Figure S4). A significant increase
Table 1 Consensus aryl hydrocarbon receptor response elements (AHREs) in human stem cell- and migration/invasion-associated
gene promoters
Gene # of Consensus AHREs and location relative to TSS
Standard Cyp1b1 8 (−206, −267, −840, −859, −944, −1028, −1678, −2392)
Stem cell markers Aldh1a1 0
Sox2 7 (−617, −749, −1284, −1430, −1678, −2577, +59)
Nanog 9 (−83, −140, −169, −430, −683, −1076, −2019, −2103, +146)
Dppa3 NA
Pou5f1 3 (−1403, −2203, −2289)
Bmi1 5 (−64, 328, −369, −2275, −2428)
Notch1 13 (−75, −284, −367, −655, −743, −982,-1270, −1838, −1844, −2114, −2140, +52, +196)
Notch2 NA
Msi1 7 (−270, −559, −904, −1821, −2114, −2686, +190)
Invasion and migration markers Snai1 5 (−82, −148, −1836, −1944, +216)
Twist1 NA
Vim 6 (−360, 384, −927, −1003, +224, +294)
Twist2 2 (−314, −2114)
Tgfb1 5 (−836, −1936, −2037, −2190, −2734)
Snai2 5 (−576, −2016, −2821, −2823, +50)
Fn1 1 (−2023)
Consensus AHREs were searched up to 3,000 bp upstream and 300 bp upstream of the transcription start site using Transcriptional Regulatory Element
Database (http://rulai.cshl.edu)
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in migration rate also was seen for ALDHhigh cells follow-
ing a 48-hour treatment with a lower TCDD dose (0.2 nM,
not shown).
Generalization of the correlation between Ahr or Cyp1b1
and BCSLC- and invasion/migration-associated genes
The experiments described above confirm that AHR
hyper-activation with FICZ induces both BCSLC- and mi-
gration/invasion-associated genes in an AHR-dependent
fashion in Hs578T cells. If these associations are
generalizable to other breast cancer cell lines, then it
would be predicted that Ahr expression and expression of
Cyp1b1, as a marker for AHR activity, would correlate, in
multiple breast cancer cell lines, with expression of the
BCSLC- and migration/invasion-associated gene sets iden-
tified in Hs578T cells. For such an analysis, we used
microarray/RNA-seq data compiled by the Broad Institute
on 79 primary human breast cancer cell lines, i.e. the
Cancer Cell Line Encyclopedia (CCLE) [66]. Use of
Cyp1b1 as a marker for AHR activity in this context is
supported by (1) our findings [15], and those of others
[67], demonstrating that baseline Cyp1b1 mRNA levels
are maintained in part by ‘constitutively active’ AHR
in human breast cancer cell lines, and (2) the obser-
vation that, of all breast cancer cell lines in the
CCLE, the nearest neighbor to Ahr of >20,000 gene
probes is Cyp1b1 (P = 0.0019; this is not to say that
there are no other factors regulating Cyp1b1 expression
[67]). Gene set enrichment analyses (GSEA) were per-
formed with the aim of testing whether the gene set listed
in Table 1 is significantly and coordinately correlated with
Ahr or Cyp1b1 expression. Indeed, Ahr expression was
significantly correlated (false discovery rate = 0.025)
with the putative AHR target gene set shown in
Table 1 (Additional file 5: Figure S5A). Similarly,
there was a significant correlation between Cyp1b1
and the expression of the putative AHR target gene
set (FDR = 0.021; Additional file 5: Figure S5B). Inter-
estingly, the ‘outlier’ with a negative correlation score
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Naive DMSO TCDD FICZ 




Naive DMSO TCDD FICZ 
C      N       C       N      C      N      C       N      C       N 
Sum149 
B(a)P 
1            1.15        2.85         1.70          3.47       
1           1.17       1.58        1.43        
SOX2 
Fig. 4 Modulation of AHR activity affects AHR binding to Cyp1b1 and Sox2 promoters and SOX2 protein production. (a) Hs578T cells were treated
with vehicle, 10 μM AHR inhibitor CH223191, 0.5 μM FICZ, or 0.5 μM FICZ + 10 μM AHR inhibitor CH223191 for 48 hours and ChIP assays were performed
with human AHR-specific antibody and Cyp1b1- or Sox2-specific promoters as described in the Materials and Methods. Data are presented as mean
fold-change ± standard error, IgG control n = 4, vehicle n = 5, CH223191 n = 4, FICZ n = 5, FICZ + CH223191 = 4. An asterisk indicates a significant
increase relative to vehicle controls, *P <0.05. A pound sign indicates a significant decrease relative to vehicle controls, #P <0.05. A cross
indicates a significant increase relative to IgG controls, +P <0.005. A caret sign indicates a significant decrease relative to FICZ treatment,
^P <0.05. Relative positions of putative AHR response elements and amplified fragments are represented in the embedded map. (b) SUM149 or
(c) MCF-7 cell cytoplasmic and nuclear protein extracts were probed for SOX2 protein expression following treatment with vehicle or AHR agonists:
0.5 μM FICZ, 10 μM B(a)P or 1 nM TCDD. C = cytoplasmic extract, N = nuclear extract. The number above each band indicates fold-change from naïve
after normalization to loading control, based on ImageJ densitometry analysis. (d) Hs578T cells were transfected with a CMV promoter-driven Sox2
plasmid and ALDH activity assayed 48 hours later. Data from four independent experiments are presented as percent ALDHhigh ± standard
error. Asterisk indicates a significant increase in the %ALDHhigh cells, *P <0.005
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(Additional file 5: Figure S5A and S5B, red arrow),
the one stem cell-associated gene we tested that did
not increase following AHR hyper-activation (Fig. 3).
To generalize results to primary human cancers, a
similar GSEA analysis was performed using transcrip-
tomic data from 977 primary human breast cancers
catalogued in the Cancer Genome Atlas (TCGA)
database [68] and 995 primary human breast cancers
in the Curtis database [69]. As shown for cell lines
in the CCLE, there was a significant association
(FDR = 0.047) between Ahr expression and the gene
set listed in Table 1 (Additional file 6: Figure S6A).
A stronger association (FDR = 0.0001) was seen be-
tween Cyp1b1 expression and expression of the puta-
tive AHR target gene set (Additional file 6: Figure
S6B). As with the CCLE database, Msi1 was not cor-
related with either Ahr or Cyp1b1 in the TCGA
database (Red arrows, Additional file 6: Figure S6A,
S6B). Similar data were obtained using the Curtis
dataset (not shown). Collectively, data mined from
three large breast cancer databases (CCLE, TCGA,
and Curtis) show a significant and generalizable
association between Ahr or AHR activity (Cyp1b1
expression) and cancer stem cell- and migration/in-
vasion-associated gene sets, an outcome consistent
with regulation of these genes by a constitutively active
(i.e. endogenous AHR ligand-activated) AHR.
Decreasing AHR activity decreases tumorsphere
formation
BCSLC can form tumorspheres and produce progenitor
cells in ultra-low adherence conditions over several pas-
sages [20, 31, 70–73]. To determine if the AHR contrib-
utes to this functional readout of BCSLCs, Hs578T cells
were cultured in Mammocult media under ultra-low ad-
herence conditions and AHR activity and expression
were modulated with CH223191 or with a dox-inducible
shAhr. Both the size and total number of tumorspheres
were significantly reduced (P <0.05–0.005) by CH223191
or a dox-induced shAhr in primary, secondary (Fig. 7a,b),
tertiary, and quaternary (not shown) cultures. No effect on
cell viability (trypan blue exclusion) was seen (the percent
viability is indicated in the upper right corner of each
image in Fig. 7a). Similar results were obtained with
CB7993113 (not shown). These results suggest that the
AHR regulates tumorsphere formation and the ability of
BCSLCs to (asymmetrically) divide and/or differentiate into
progenitor cells in low-adherence, selective conditions,
and/or controls the ability of progenitor cells to divide.
AHR controls expression of cancer stem cell-associated
properties in an inflammatory breast cancer cell line
IBC is a particularly aggressive form of cancer charac-
terized by a ~50 % survival rate at 2 years [74]. To




































































































































































































































C A B ALDHhigh vs ALDHlow                                     ALDHlow, Veh vs FICZ                         ALDH high, Veh vs FICZ 
Fig. 5 AHR hyper-activation increases expression of migration and invasion-associated genes in Hs578T cells. Hs578T cells were treated with vehicle or
0.5 μM FICZ for 48 hours, sorted into ALDHhigh and ALDHlow cells, and then assayed by RT-qPCR for the relative levels of the seven migration and
invasion-associated genes indicated. Gene expression was then normalized to Gapdh mRNA levels and fold-change from vehicle-treated ALDHlow or
ALDHhigh cells was calculated. Data from nine independent experiments are presented as mean fold-change ± standard error. In all cases, statistical
significance was determined with the Wilcoxon rank sum test to determine if the distributions of results, relative to 1 as the standard (represented by
the dotted line on each graph), are different between the comparison groups. Asterisks indicate a significant increase in the mRNA fold-change,
*P <0.05, **P <0.005, ***P <0.0005. (a) Migration- and invasion-associated gene expression levels were normalized to expression levels in vehicle-treated
ALDHlow cells and the distribution of outcomes from vehicle-treated ALDHhigh versus vehicle-treated ALDHlow cells was compared. (b) Gene expression
levels were normalized to expression levels in vehicle-treated ALDHlow cells and the distribution of outcomes from vehicle-treated ALDHlow versus
FICZ-treated ALDHlow cells was compared. (c) Gene expression levels were normalized to expression levels in vehicle-treated ALDHhigh cells and
the distribution of outcomes from vehicle-treated ALDHhigh versus FICZ-treated ALDHhigh cells was compared
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is generalizable to this cancer subtype, SUM149 cells,
derived from an IBC, were studied for expression of
Ahr and Cyp1b1 in ALDHhigh and ALDHlow subpopu-
lations, for the contribution of the AHR to ALDH1
activity, and for the ability to form tumorspheres. As
shown for TNBC Hs578T cells, ALDHhigh SUM149
cells expressed significantly higher Ahr and Cyp1b1
levels than ALDHlow cells (P <0.05–0.005; Fig. 8a).
CH223191 or Ahr-specific shRNA significantly de-
creased AHR activity or expression greater than 60 %
(P <0.01–0.0001; Fig. 8b), the percentage of ALDHhigh
cells by over 80 % (P <0.05–0.0005; Fig. 8c,d), and overall
ALDH1 activity in the entire population (not shown).
Conversely, FICZ, β-NF, TCDD, and DMBA significantly
increased the percentage of ALDHhigh cells (P <0.01–
0.005; Fig. 8c,d) and CH223191 treatment in tandem sig-
nificantly reduced this increase (P <0.05–0.01; Fig. 8c,d).
Finally, fewer and smaller tumorspheres were formed
following CH223191 treatment (P <0.05–0.01; Fig. 8e,f).
No changes in cell viability were detected (the percent
viability is indicated in the upper right corner of each
image in Fig. 8e). These data parallel those found with
Hs578T cells (Fig. 7) and suggest that AHR control
of these stem cell properties is generalizable to other
ER− breast cancer subtypes.
Decreasing AHR activity decreases chemoresistance, a
hallmark of BCSLCs
Chemoresistance is another widely studied functional
BCSLC marker [21, 22, 53, 72, 73, 75, 76]. To determine
if the AHR influences chemoresistance, ALDHhigh and
ALDHlow Hs578T cells were treated with titrated doses
of adriamycin or paclitaxel, chemotherapeutics with dis-
tinct mechanisms of action, with or without CH223191.
Cell viability was assayed 24 hours later. As expected of
BCSLCs, ALDH
high cells were more resistant to the che-
motherapeutics than ALDHlow cells (see half maximal
effective concentrations (EC50) in Table 2). CH223191
had no effect on viability (not shown). However,
CH223191 significantly (P <0.05–0.005) increased sensi-
tivity to both adriamycin and paclitaxel in both ALDHlow
and ALDHhigh cells (Fig. 9). The EC50 of adriamycin-
treated ALDHhigh cells (EC50 = 1.99 μM) was three times
greater than that of adriamycin + CH223191-treated cells
(EC50 = 0.60 μM; Fig. 9b; Table 2). These results are con-
sistent with previous reports demonstrating AHR con-
trol of chemotherapeutic-induced breast cancer cell
apoptosis [77]. Furthermore, they indicate that migra-
tion/invasion-associated genes, and functional markers
of BCSLCs (tumorsphere formation, rapid migration,





























































































Fig. 6 AHR down-regulation decreases migration of SUM149 cells. (a) Presented are representative images of SUM149 cell migration at 24 and
48 hours after cells were sorted into ALDHhigh and ALDHlow populations, cultured to confluence, scratched, and treated with vehicle or 10 μM
CH223191. Data are representative of three independent experiments. Black lines indicate the borders of the original scratch. (b) SUM149 cells
were treated as in (a) and percent exposed area was quantified. Data from three experiments were normalized to results obtained with naïve cells
and presented as mean percent exposed area ± standard error. Asterisks indicate a significant increase in exposed area, *P <0.05, **P <0.0005.
A cross indicates a significant decrease in exposed area, +P <0.05
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shAhr-mediated AHR knockdown decreases expansion of
tumors initiated with ALDHhigh and ALDHlow SUM149 cells
Cancer stem cells tend to generate tumors more efficiently
in vivo than non-cancer stem cells [18–20, 31, 72]. To de-
termine if AHR, which increases expression of stem cell-
associated properties in vitro, influences tumor cell fate in
vivo, SUM149 cells, stably transduced with a dox-
inducible shAhr (Fig. 8), were sorted and 3,000 ALDHhigh
and ALDHlow cells were injected into the right and left
mammary fat pads, respectively, of female NOD/SCID
mice. Half of the mice were given doxycycline-containing
water to induce the shAhr. ALDHhigh cells generated palp-
able tumors more rapidly and these tumors grew faster
than ALDHlow cells (growth rates of 0.26 vs. 0.19 mm/day,
P <0.0001; Fig. 10a). Furthermore, dox-induced shAhr sig-
nificantly reduced growth rates from 0.26 to 0.18 and
from 0.19 to 0.11 mm/day in ALDHhigh and ALDHlow
cells, respectively (P <0.0005; Fig. 10b,c). Consistent with
in vitro experiments, Ahr, Cyp1b1, Aldh1a1, and Sox2
mRNA levels were reduced in tumors from doxycycline-
treated mice (Fig. 11).
Although ALDH1 activity and Aldh1 expression have
been identified as a valid marker for BCSLCs [19, 23, 50,
53, 78] and despite ALDHhigh cells having formed tumors
sooner than ALDHlow cells in the experiment described
above, we wanted to confirm that ALDHhigh cells, in our
hands, exhibit a hallmark property of cancer stem cells in
vivo, i.e. efficient formation of tumors following xenograft-
ing. Therefore, SUM149 cells, stably transduced with a
different doxycycline-inducible shAHR, were sorted into
ALDHhigh and ALDHlow subpopulations and xenografted
at titered numbers (10,000, 5,000, 2,500 cells) into the
Passage 1 
Passage 2 
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Fig. 7 AHR down-regulation decreases Hs578T tumorsphere formation. (a) Dox-inducible shAhr-transduced Hs578T (‘shAhr’) or wildtype Hs578T
cells were left untreated or treated for 48 hours with vehicle, doxycycline, or 10 μM CH223191 as indicated and cultured in Mammocult media
under ultra-low adherence conditions. Representative images of primary (day 8) and secondary (day 16, following passage at day 8) tumorspheres
are presented. The percentage of viable cells is included on each image. Vehicle and CH223191 treatment groups are representative of six independent
experiments. shAHR, no dox and shAHR+ dox treatment groups are representative of five independent experiments. (b) Hs578T cells were treated as in
(a) and tumorsphere formation was quantified. Data from six experiments were normalized to results obtained with naïve cells and presented as mean
fold-changes from naive ± standard error. Asterisks indicate a significant decrease in the percentage of tumorspheres, *P <0.05, **P <0.005
Stanford et al. BMC Biology  (2016) 14:20 Page 10 of 22
mammary fat pads of female NOD/SCID recipients
(six mice/group). Tumor volume was then tracked over a
69-day period. As predicted of tumors derived from cells
with cancer stem-like properties, tumors generated from
ALDHhigh cells were detected sooner than tumors gener-
ated from ALDHlow cells at each respective cell number,
thereby demonstrating a consistently higher efficiency of
tumor initiation (Figs. 12 and 13). Tumors grew faster
after xenograft of 10,000 ALDHhigh as compared with
ALDHlow cells. Furthermore, induction of shAhr with
doxycycline significantly delayed tumor formation and
subsequent growth of tumors generated from both
ALDHhigh cells and ALDHlow cells regardless of cell num-
ber transferred to recipients. These data strongly support
the use of ALDH activity as a marker for breast cancer cells
with cancer stem cell-like properties and the conclusion
Fig. 8 AHR modulation affects markers associated with BCSLC in SUM149 cells. (a) Ahr, Cyp1b1 and Aldh1a1 mRNA expression in sorted ALDH
high
and ALDHlow SUM149 cells was quantified by RT-qPCR. Data from three independent experiments were analyzed using the Pfaffl method, normalized
to the Gapdh signal, and presented as mean fold-change from ALDHlow ± standard error. Asterisks indicate a significant increase in the mRNA
fold-change, *P <0.05, **P <0.01, ***P <0.005. (b) Wildtype or dox-inducible shAhr-transduced SUM149 cells were transfected, treated and
quantified as indicated in Fig. 2a. Data are presented as mean ± standard error. Left panel n = 5, center panel n = 4, right panel n = 6. Asterisks
indicate a significant decrease in the mRNA fold-change or reporter activity, *P <0.01, **P <0.001, ***P <0.0001. (c) Representative flow cytometry plots
of ALDEFLUOR™ staining of dox-inducible shAhr-transduced SUM149 cells cultured, treated, and depicted as described in Fig. 2b. (d) Dox-inducible
shAhr-transduced or wildtype SUM149 cells were treated, stained, and quantified as in Fig. 2c. Data were normalized to results obtained with naïve cells
(mean baseline =10.4 % ALDHhigh cells) and presented as mean fold-change from naive ± standard error. shAHR-dox n = 4, shAHR + dox n = 4, DMSO
n = 12, CH223191 n = 5, FICZ n = 6, FICZ + CH223191 n = 5, β-NF n = 4, β-NF + CH223191 n = 4, TCDD n = 8, TCDD+ CH223191 n = 3, DMBA n = 5, and
DMBA + CH223191 n = 3. Asterisks indicate a significant decrease in the percentage of ALDHhigh cells, *P <0.05, **P <0.01, ***P <0.0005. A cross
indicates a significant increase in ALDHhigh cells, +P <0.01, ++P <0.005. (e) Representative images of primary (day 8) and secondary (day 16)
tumorspheres after SUM149 cells were treated for 48 hours with vehicle or 10 μM CH223191. The percent viable cells are included on each
image. Data are representative of four independent experiments. (f) SUM149 cells were treated as in (e) and tumorsphere formation was quantified.
Data from four experiments were normalized to results obtained with naïve cells and presented as mean fold-change from naive ± standard error.
Asterisks indicate a significant decrease in the percentage of tumorspheres, *P <0.05, **P <0.01
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that AHR influences the efficiency with which all cells
along a continuum of low to high ALDH expression
can initiate tumors.
Discussion
Accumulating data suggest that the AHR plays an import-
ant role in breast cancer, in general, and in progression to
end-stage invasion and migration in particular. For ex-
ample, the AHR is hyper-expressed and transcriptionally
active in most TNBC and IBC cell lines, and its expression
is associated with tumor invasion [10, 13, 15, 79]. The data
presented here strongly suggest that the AHR drives
tumorigenesis in part through induction or maintenance
of cells with cancer stem cell-like properties.
The involvement of the AHR in BCSLC biology is sug-
gested by its emerging role in normal tissue-specific
stem cell development. For example, the AHR, presum-
ably activated by endogenous ligand(s), helps maintain
hematopoietic stem cell self-renewal and block differen-
tiation [36, 37, 80], and drives bipotential blood stem cell
differentiation [39]. AHR repression in embryonic stem
cells likely maintains pluripotency, and the AHR controls
embryonic stem cell differentiation into cardiomyocytes
[38]. Data presented here extend these studies by demon-
strating that the AHR is involved in the phenotype
(ALDH1 activity and Aldh1a1 expression), genomics
(up-regulation of stem cell- and migration/invasion-
associated genes), and function (migration, chemore-
sistance, tumorigenicity) of BCSLCs.
Elevated ALDH expression identifies BCSLCs and is
associated with increased expression of chemoresistance
proteins, increased tumor cell invasion, higher tumor
grade, and poor survival in breast cancer patients
[19, 21, 28, 32, 53]. Indeed, in our hands, ALDHhigh
cells exhibited increased chemoresistance (Fig. 9), elevated
expression of stem cell- and migration/invasion-associated
genes (Figs. 3 and 5), faster migration (Fig. 6), higher
tumor-initiating capacity and increased tumor growth
rates in vivo (Figs. 10, 12 and 13). AHR control of che-
moresistance is particularly interesting given important
Table 2 Half maximal effective concentrations (EC50) of two
chemotherapeutics in the presence or absence of an AHR
inhibitor
Cell population Drug treatment Chemotherapeutic EC50 (μM)
ALDHlow Paclitaxel 0.81
ALDHlow Paclitaxel + CH 0.56
ALDHhigh Paclitaxel 1.21
ALDHhigh Paclitaxel + CH 0.76
ALDHlow Adriamycin 0.55
ALDHlow Adriamycin + CH 0.20
ALDHhigh Adriamycin 1.99
ALDHhigh Adriamycin + CH 0.60







































































































Fig. 9 AHR down-regulation decreases chemotherapeutic resistance of both ALDHhigh and ALDHlow Hs578T cells. MTT assays were used to measure
cell viability after Hs578T cells were sorted into ALDHlow (a and c) and ALDHhigh (b and d) populations and treated with adriamycin (a and b) or
paclitaxel (c and d) with and without 10 μM CH223191 for 24 hours. CH223191 treatment alone did not affect cell viability (≥95 % viability in
the presence or absence of CH223191 only). Data from six independent experiments were normalized to vehicle-treated cells and presented as mean
percent viable cells ± standard error. Asterisks indicate a significant increase in cell death, *P <0.05, **P <0.005, ***P <0.005
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recent studies demonstrating that TCDD decreases and
AHR inhibition increases apoptosis induced by UV light
or chemotherapeutics in six breast cancer cell lines [77].
AHR-mediated chemoresistance takes on even greater sig-
nificance given recent studies showing that chemoresis-
tance may be a more meaningful marker of metastatic
behavior than markers of epithelial-to-mesenchymal tran-
sition [25]. These data support the hypothesis that AHR
inhibitors may represent effective, targeted therapeutics
when used in combination with conventional chemothera-
peutics. Collectively, these data strongly support the con-
clusion that ALDHhigh cells are at least breast cancer
stem-like cells if not bona fide breast cancer stem cells.
We previously demonstrated that constitutively active
AHR in breast cancer lines preferentially drives Cyp1b1
expression while an exogenous ligand, e.g. DMBA, tends
to induce greater fold-increases in Cyp1a1 than Cyp1b1
[15]. Interestingly, higher relative levels of Cyp1b1 were
noted in ALDHhigh cells, as compared with ALDHlow
cells (Fig. 3a), suggesting the possibility that a higher
level of AHR activity, as represented by baseline Cyp1b1
levels, characterizes ALDHhigh-stem like cells.
AHR hyper-activation with FICZ increased expression
of Aldh1a1 and stem cell-associated genes demonstrat-
ing a causal relationship between AHR activity and ex-
pression of these genes (Fig. 3b,c). This gene set has
been implicated in generating both normal tissue stem
cells and BCSLCs. Notch1 and Notch2 are critical to
symmetric and asymmetric cell division, stem cell differ-
entiation in embryonic and adult stem cells [26, 81], and
are potential therapeutic targets [76, 82]. Bmi1 is re-
quired for the maintenance of somatic stem cells
through repression of cellular senescence and cell death
[83], and is involved in the control of BCSLC growth,
chemoresistance, and tumorsphere formation [84]. Stella
is involved in maintenance of gene-specific DNA methy-
lation in the early embryo, and is a marker for some
BCSLC types [85]. Sox2, Oct4 and Nanog are traditional
embryonic stem cell markers used to reprogram cells to
a pluripotent state, and are expressed at elevated levels
in BCSLCs [27, 30, 85, 86]. Sox2 is up-regulated in
TNBCs and has been implicated in tumorsphere forma-
tion and control of tumor initiation [27, 62, 63]. There-
fore, the finding that the AHR directly interacts with the
Sox2 promoter (Fig. 4a) strongly suggests that the AHR
is at the apex of an important signaling pathway that
controls cancer progression by increasing phenotypic
and functional expression of cancer stem cell-associated
markers within the tumor cell population.
Our data also suggest that the AHR plays a key role in
regulating BCSLC migration. Snail, Slug, Twist1, Twist2,
Tgfb1, and Fibronectin (Fn1), which contribute to cell in-
vasion and cell migration [28, 87, 88], are all up-regulated
in FICZ-treated ALDHhigh cells (Fig. 5c). As would be pre-
dicted from these results, AHR inhibition slows (Fig. 6)
and AHR hyper-activation accelerates (Additional file 4:
Figure S4) cell migration in the scratch-wound assay.
Importantly, these findings on AHR-regulated genes
appear generalizable since strong correlations were seen
between Ahr or Cyp1b1 and the stem cell- and
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Fig. 10 AHR down-regulation decreases tumor formation in xenograft mice. (a) Doxycycline-inducible shAhr-expressing SUM149 cells were sorted
for ALDHhigh or ALDHlow activity and 3,000 cells were grafted into the mammary fat pads of NOD/SCID mice (10 mice/group). Tumor volumes
were measured over the next 56 days. Data are presented as mean tumor volume ± standard error; P <0.0001. The average rate of tumor growth
of tumors initiated with ALDHhigh cells (0.26 mm/day) was significantly different than the rate of growth of tumors initiated with ALDHlow cells
(0.19 mm/day), P <0.0005. A cross indicates a significant increase in average tumor size beginning at day 25, +P <0.01. (b) Doxycycline-inducible
shAhr-expressing SUM149 cells were sorted for low ALDH expression and 3,000 cells were grafted into the mammary fat pads of NOD/SCID mice.
Mice then were given water + 5 % sucrose or water with doxycycline + 5 % sucrose and tumor volumes were quantified over the next 56 day
period. The average rate of tumor growth of ALDHlow cells in control mice (0.19 mm/day) was significantly different than that of ALDHlow cells in
dox-treated mice (0.11 mm/day), P <0.0005. (c) Doxycycline-inducible shAhr-expressing SUM149 cells were sorted for high ALDH expression and
3,000 cells were grafted into the mammary fat pads of NOD/SCID mice. Mice were then given water + 5 % sucrose or water with doxycycline +
5 % sucrose. Tumor volumes were measured over the next 56 day period. The average rate of tumor growth in water-treated control mice
(0.26 mm/day) was significantly different than the rate of tumor growth in dox-treated mice (0.18 mm/day), P <0.0005. A cross indicates a
significant increase in tumor size beginning at day 25, +P <0.01
Stanford et al. BMC Biology  (2016) 14:20 Page 13 of 22
migration/invasion-associated gene sets in databases of
79 human breast cancer cell lines characterized in the
CCLE and over 1850 primary human breast cancers cat-
alogued in the TCGA and Curtis databases (Additional
files 5 and 6: Figure S5 and S6). Furthermore, these
results suggest the possibility that the AHR contrib-
utes to cell invasion and migration through up-
regulation of stem cell- and invasion/migration-associ-
ated genes.
Consistent up-regulation of CYP1B1 in breast cancers
[89] suggests that this enzyme plays an important role in
cancer, potentially by influencing cell migration [90]. It
is, therefore, formally possible that at least some of the
effects observed here reflect AHR ligand binding to
CYP1B1. While this possibility cannot be ruled out, par-
ticularly for ligands such as FICZ, which are metabolized
by CYP1B1 [91], it seems unlikely as a general rule since
TCDD, which is not metabolized by CYP1B1 and does
not bind CYP1B1 (data not shown), generates the same
outcomes (increase in stem cell-associated genes, cell
migration) as the other ligands.
AHR inhibition or knockdown in either Hs578T or
SUM149 cells significantly reduced the number and size
of tumorspheres formed in low adherence conditions
over several generations (Figs. 7 and 8e,f ). The forma-
tion of these colonies is generally considered to be a
function of asymmetric BCSLC division and production
of progenitor cells which constitute the majority of the
cells in the spheres [31, 70, 72]. Therefore, it is possible
that the AHR controls the asymmetric differentiation of
BCSLC and/or the growth of their progenitors.
Furthermore, AHR knockdown with either of two
shAhr constructs significantly slowed the initiation and
outgrowth of both ALDHlow and ALDHhigh cell-derived
tumors (Figs. 10b, c, 12b, c, 13). This decrease in tumor
outgrowth was accompanied by a decrease in Cyp1b1,
Aldh1a1, and Sox2 expression (Fig. 11), further linking
AHR activity to expression of these genes.




















































































Fig. 11 AHR down-regulation decreases expression of Ahr, Aldh1a1, Cyp1b1, and Sox2 in xenografted mouse tumors. Twenty NOD/SCID mice were
injected with 3,000 dox-inducible shAhr-transduced ALDHhigh or ALDHlow SUM149 cells as described in Fig. 10. Half of the mice were provided with
water containing 2 mg/mL doxycycline to induce the shAhr and tumors were harvested after 42–72 days when they reached 15 mm in total
size (control mice n = 20, mice with doxycycline treatment n = 19). (a) Ahr, (b) Cyp1b1, (c) Aldh1a1, and (d) Sox2 mRNA expression levels
were assayed by RT-qPCR. Since the AHR controls expression of Cyp1b1, Aldh1a1, and Sox2 in both ALDHhigh and ALDHlow cells (e.g. Fig. 3),
data generated with tumors from ALDHhigh and ALDHlow tumors were pooled for statistical purposes. Data are presented as fold-change
relative to the average CT value from control mice, i.e. no dox, grafted with ALDHlow cells ± standard error. Asterisks indicate a significant
decrease in the mRNA fold-change, *P <0.05, **P <0.01, ***P <0.005
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Results presented here are reminiscent of several studies
demonstrating that baseline (endogenous ligand-induced)
AHR activity in immortalized cells favors tumor growth
or aggressive behavior [12–14, 92–97]. Paradoxically,
several studies indicate that exogenous AHR ligands
can reduce tumor growth or invasion [41, 92, 96, 97].
As elegantly described in a recent review [98], these
seemingly contradictory results may, in part, reflect
context- or tumor stage-specific differences. For example,
AHR agonists may inhibit growth in ER+ breast cancers in
part through AHR-mediated down-regulation of ER
expression or activity [41]. However, in similar cell
types [47, 99, 100], similar AHR agonist- and antagonist-
mediated outcomes could be due to more subtle effects
on AHR activation or signaling. For instance, it has been
postulated that, while endogenous AHR ligands drive sig-
naling towards, for example, increased invasion, exogen-
ous AHR ligands ‘divert’ [10] or ‘disrupt’ [92] the response
towards signaling pathways which oppose tumor invasion,
e.g. differentiation [47]. Furthermore, exogenous ligands,
e.g. Tranilast, that decrease invasion [99, 100], may act as
partial agonists that compete with endogenous ligands for
AHR binding but which are weaker activators of AHR
transcriptional activity, thereby reducing baseline AHR
































































































































































































































































Fig. 12 AHR down-regulation decreases the efficiency of tumor formation in vivo. Titered numbers (10,000, 5,000, or 2,500) of sorted ALDHhigh or
ALDHlow dox-inducible shAhr-transduced SUM149 cells were grafted into the mammary fat pads of NOD/SCID mice (six mice/group). Mice were
given water + 5 % sucrose or water with doxycycline + 5 % sucrose to induce the shAhr. Data are presented as mean tumor volume ± standard
error. Asterisks indicate a significant difference in tumor volume, P <0.05. Statistical analyses were not performed when none of the mice in a
given control group developed tumors at that time point
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signaling [101]. Finally, outcomes may be ligand-, cell sub-
set-, or dose-specific. Thus, high affinity AHR ligands,
such as TCDD, induce stem cell characteristics including
ALDH expression and accelerated migration, particularly
at low doses (e.g. 0.2–1 nM; Additional file 4: Figure S4,
and data not shown), while higher doses (10 nM) may re-
duce invasiveness of the majority non-BCSLC population
[47].
Finally, a limited number of previous studies have ad-
dressed the role of the AHR in breast cancer stem cell
generation [96, 97, 99, 102]. While these studies all point
towards a role for the AHR in cancer stem-like cell gen-
eration, there is as yet no clear consensus on how this
occurs or even on whether the AHR favors or inhibits
BCSLC production/function. For example, Zhao et al.
[96] showed that AHR activation with β-NF or 3-MC or
over-expression of a PasB mutant AHR decreased
tumorsphere formation; in our hands, only 3-MC re-
duced secondary tumorsphere formation in SUM149
and MCF-7 cells (data not shown). In what may seem
like a contradiction, Zhao et al. [97] later published that
MCF-7 mammosphere formation was suppressed by
AHR inhibition with CH223191 as well as by siRNA-
mediated AHR knockdown in MDA-MB-453 cells. In
Dubrovska et al. [102], AHR inhibitors reduced the per-
centage of ALDHhigh MCF-7 cells in tamoxifen-resistant
MCF-7 (as shown in our studies with triple negative
Hs578T and SUM149 cells) but produced the opposite
effect in wildtype MCF-7 cells. At least some of these
differences can be attributed to the different subtypes of
breast cancer cells (i.e. ER+, Luminal A-type or Her-2
over-expressing MCF-7 cells versus ER−, basal-like, triple
negative Hs578T and SUM149 cells). In any case, further
experimentation is required to determine how the AHR
influences ‘stem-ness’ in breast cancer cells.
Conclusions
Studies presented here indicate that the AHR influences,
in TNBC and IBC cells, critical markers associated with
‘stem-ness’. The ability of several exogenous AHR ligands,
including TCDD and DMBA to up-regulate phenotypic,
genomic, and/or functional markers of BCSLCs strongly
suggests the potential for ubiquitous environmental AHR
ligands to accelerate progression to lethal, invasive can-
cers. Furthermore, the demonstration that AHR inhibition
significantly reduces expression of these phenotypic and
functional cancer stem cell markers encourages the testing
of AHR inhibitors, for example, to significantly increase
the sensitivity of BCSLCs to conventional chemotherapeu-
tics. In general, these results suggest that non-toxic
AHR modulators may represent important therapeutics
for otherwise refractory TNBC and IBC, and potentially
for brain and other cancers in which the AHR appears
to play a role.
Methods
Chemicals
DMSO, β-NF, DMBA, TCDD, paclitaxel, doxorubicin,
and doxycycline were obtained from Sigma-Aldrich
(St. Louis, MO). FICZ, CH223191, and CB7993113 were
provided by Dr. M. Pollastri (Northeastern University).
Cell line acquisition, cell culture, and media
Hs578T and MCF-10F cells were purchased from
ATCC and cultured according to ATCC recommenda-
tions (ATCC, Manassas, VA). SUM149 cells were a gen-
erous gift from Dr. Stephen Ethier (Wayne State
University, Detroit, MI). SUM149 cells were maintained
in F-12 K Medium (Mediatech, Herndon, VA) contain-
ing 5 % FBS (Sigma-Aldrich), 0.5 μg/mL hydrocortisone





































































Fig. 13 Percent of mice bearing tumors 43 days after receiving orthotopic xenografts of 10,000, 5,000, or 2,500 ALDHhigh or ALDHlow SUM149
cells. The percentage of mice with palpable tumors at day 43 of the experiment presented in Fig. 12 was determined as a measure of tumor
initiation efficiency. Mice were given either (a) water + 5 % sucrose (n = 20) or (b) water with doxycycline + 5 % sucrose to induce expression of
shAHR (n = 20)
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penicillin/100 μg/mL streptomycin (Mediatech), 10 μg/
mL insulin (Sigma-Aldrich), and 5 μg/mL Plasmocin
(Invivogen, San Diego, CA).
Inducible, stable Ahr-specific shRNA cells
Doxycycline (dox)-inducible TurboRFP-shAhr TRIPZ lenti-
viral vectors (Open Biosystems, Huntsville, AL) were used
to make viral transduction particles. Hs578T and SUM149
cells were transduced at optimal MOIs of 25 and 50, re-
spectively, in medium containing hexadimethyrine bromide
(8 μM g/mL polybrene; Sigma-Aldrich). Transduced cells
were maintained in 1.5 μg/mL puromycin (Invitrogen,
Grand Island, NY). RFP expression was maximal 48 hours
after dox treatment (1.5 μg/mL) of transduced cells. For in
vivo experiments, two different inducible shAHR plasmids
were constructed and used to generate two independent
doxycycline-inducible shAHR-expressing SUM149 lines.
ALDEFLUOR™ staining
Cells were dosed with 0.5 μM FICZ, 1 μM β-NF, 10 μM
CH223191, 10 μM CB7993113, 1 nM TCDD, 1 μM
DMBA, 1.5 μg/mL dox, vehicle (0.1 % DMSO), and/or left
untreated every 24 hours. After 48 hours, ALDEFLUOR™
assays were performed according to the manufacturer’s in-
structions (Stem Cell Technologies, Vancouver, Canada).
Briefly, cells (106 cells/mL) were treated with 5 μL/mL
ALDEFLUORTM substrate in 1 mL of ALDEFLUORTM
buffer. Negative controls were treated with both ALDE-
FLUORTM substrate and 50 mmol/L diethylaminobenzal-
dehyde (DEAB), an ALDH-specific inhibitor. Samples were
incubated for 35 minutes at 37 °C in the dark. After 35 mi-
nutes, cells were centrifuged, the supernatant was removed
and the remaining pellet was suspended in ice-cold ALDE-
FLUORTM buffer and kept on ice. Before samples were read
on the flow cytometer, propidium iodine was added
(1.5 μg/mL) to quantify viability (propidium iodine was not
used on TurboRFP-shAhr transduced cells due to overlap-
ping emissions). Cells were immediately assayed with an
LSRII flow cytometer (Becton Dickinson Biosciences, San
Jose, CA) using DEAB controls as baselines to gate ALDH-
high and ALDHlow cell populations. ALDHhigh and ALDHlow
cells were sorted on a MoFlo Legacy (Beckman Coulter, In-
dianapolis, IN). All flow cytometry data was analyzed using
Flowjo software (Ashland, OR) according to Stem Cell
Technologies’ manufacturer instructions. Briefly, DEAB-
treated control samples were used to make ALDHhigh and
ALDHlow gates as pictured in Fig. 1. The percent of cells
that fell into each gate was then quantified as ALDHhigh or
ALDHlow subsets.
Western blotting
Cells were lysed and protein extracted using NE-PER Nu-
clear and Cytoplasmic Extraction Reagents (ThermoFisher
Scientific, Grand Island, NY), according to manufacturer
instructions. Protein concentration was then quantified via
a Bradford protein assay. Equal amounts of protein (40 μg)
were subjected to 10 % SDS-PAGE and then transferred to
a nitrocellulose membrane. Non-specific binding sites were
blocked with blocking buffer containing Tris-buffered
saline and 0.1 % Tween-20 with 5 % nonfat milk powder
for 1 hour at room temperature, and the blot was incubated
with specific antibody in blocking buffer (SOX2, Lamin
A/C and α-Tubulin antibody in 1:1000 dilution, respect-
ively) at 4 °C overnight. After washing, the blot was
incubated with an appropriate secondary antibody conju-
gated with horseradish peroxidase for 1 hour at room
temperature. After washing, the detection was performed
using the enhanced chemiluminescence system. The anti-
body of SOX2 was purchased from Cell Signaling
Technology (Danvers, MA; Cat #: 2748), Lamin A/C from
Cell Signaling Technology (Cat #: 2032), and α-Tubulin
from EMD Millipore (Billerica, MA; Cat #: CP06). Image J
(National Institutes of Health, Bethesda, MD) was used to
perform densitometry analysis. Fold-change from naïve is
presented following normalization to loading control
(Lamin A/C for nuclear extract and α-tubulin for cytoplas-
mic extract).
Tumorsphere formation
Cells were treated as above. After 48 hours, cells were
harvested, dosed, and 3 × 103 cells plated in complete
MammoCult Medium (STEMCELL Technologies) con-
taining 0.5 μM hydrocortisone, 2 mM L-glutamine,
100 IU penicillin/100 μM g/mL streptomycin, and 1 %
methylcellulose (Sigma Aldrich) in ultra-low adherent
24-well plates (Corning Inc.). Colonies were quantified
with a Celigo S Imaging Cytometer (Brooks Automation,
Chelmsford, MA) after 8 days. For secondary sphere for-
mation, tumorspheres were mechanically and enzymati-
cally dissociated into a single cell suspension, re-dosed,
re-plated, and imaged as above.
RT-qPCR
mRNA was extracted using RNeasy® Plus Mini Kit
(Qiagen, Valencia, CA) and cDNA prepared using the
GoScript™ Reverse Transcription System (Promega,
Madison, WI) with a 1:1 mixture of random and Oligo
(dT)15 primers according to manufacturer’s instructions.
All RT-qPCR reactions were performed using the GoTaq®
RT-qPCR Master Mix System (Promega). Validated
primers were purchased from Qiagen Inc. (Valencia, CA):
human Cyp1b1 – QT00209496, Cyp1a1 – QT00012341,
Twist1 – QT00011956, Snai1 – QT00010010, Snai2 –
QT00044128, VIM – QT00095795, Twist2 –
QT02454004, FN1 – QT00038024, Notch1 –
QT01005109, Notch2 – QT00072212, Aldh1a1 –
QT00013286, Aldh1a3 – QT00077588, Pou5f1 –
QT00210840, Sox – QT00237601, Nanog – QT01844808,
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Dppa3 – QT01667197, Msi1 – QT00025389, Human
Bmi1 – QT00052654, Tgfb1 – QT00000728, Ahr –
QT02422938, and Gapdh – QT01192646. RT-qPCR reac-
tions were performed using a 7900HT Fast Real-Time
PCR instrument (Applied Biosystems, Carlsbad, CA), with
hot-start activation at 95 °C for 2 min, 40 cycles of de-
naturation (95 °C for 15 sec), and annealing/extension
(55 °C for 60 sec). Relative gene expression was deter-
mined using the Pfaffl method [103] and the threshold
value for Gapdh mRNA was used for normalization.
Chromatin immunoprecipitation (ChIP) assay
ChIP studies were performed using an AHR-specific anti-
body (ab2769; Abcam, Cambridge, MA) and the ChIP kit
(ab500; Abcam) according to the manufacturer’s protocol.
Cells were fixed and sonicated to produce fragments
averaging 500 bp. Following immunoprecipitation with
AHR-specific antibody or normal mouse IgG (Santa
Cruz Biotechnology, Dallas, TX), DNA was purified
and amplified using the following primers: Cyp1b1 primer:
5’-GTTTGGCGCTGGGTTAC-3’ and 5’-AGGTCGGAG
CTGACTCTCT-3’ [104], Sox2 primer: 5’-CTGTGAG
AAGGGCGTGAGAG-3’ and 5’- AAACAGCCAGTGCA
GGAGTT-3’. The relative DNA amount was calculated
using the ΔΔCt method. AHR and IgG control pull-down
signal were normalized to input signal.
Transient transfection
Hs578T or SUM149 cells were co-transfected with
the pGudluc reporter plasmid (0.5 μg) (generously
provided by Dr. M. Denison, UC, Davis), and CMV-
green (0.1 μg; for normalization) using TransIT-2020
transfection reagent (Mirus, Madison, WI). The trans-
fection medium was replaced after 24 hours. The cells
were left untreated or dosed with vehicle (DMSO,
0.1 % final concentration), 0.5 μM FICZ or CH223191
(10 μM), and harvested after 24 hours in Glo Lysis
Buffer (Promega, San Luis Obispo, CA). Luciferase ac-
tivity was determined with the Bright-Glo Luciferase
System according to the manufacturer’s instructions
(Promega). Luminescence and fluorescence were de-
termined using a Synergy2 multifunction plate reader
(Bio-Tek, Winooski, VT).
Scratch-wound assay
ALDHhigh and ALDHlow cells were sorted and grown to
confluence in 12-well plates. A p200 pipet tip was used
to make an ‘X’ in each well and non-adherent cells were
removed with PBS washes. Media was added and cells
treated with vehicle, 10 μM CH223191, 1 nM TCDD, or
0.5 μM FICZ. Media was changed and cells were re-
dosed daily. TScratch software (Tobias Gebäck and
Martin Schulz, ETH Zürich) was used to quantify the
closure of the scratch over time.
Mouse model
Eight-week old, female non-obese diabetic-severe combined
immunodeficiency (NOD/SCID) mice were purchased
from Jackson Laboratory (Bar Harbor, ME). To determine
if the AHR influences this parameter of BCSLCs, two separ-
ate in vivo experiments were performed. For both experi-
ments, SUM149 cells that were stably transduced with
either of two dox-inducible shAHR were sorted into
ALDHhigh and ALDHlow cell populations. For the first in
vivo experiment, 3000 ALDHhigh and ALDHlow cells in
100 μL of 50:50 Matrigel/DMEM were injected into the
right and left mammary fat pads, respectively, of female
NOD/SCID mice. For the second in vivo experiment,
titered numbers (2,500, 5,000, or 10,000) of ALDHhigh and
ALDHlow cells in 100 μL of 50:50 Matrigel/DMEM were
injected into the right and left mammary fat pads, respect-
ively, of female NOD/SCID mice. For both experiments,
control mice drank water with 5 % sucrose, while the
treated mice were provided with water containing 5 % su-
crose and 2 mg/mL doxycycline to induce the shAHR.
Tumor growth was quantified using Vernier calipers and
animals were sacrificed when the total tumor burden
reached 15 mm. No metastases were noted at this time.
Necropsies were performed to resect the tumors from both
sides. RNA was isolated from each of the primary tumors
for gene expression analyses for the first in vivo experiment.
Animals were housed at the Association for Assessment
and Accreditation of Laboratory Animal Care certified Bos-
ton University Medical Laboratory Animal Science Center
and used in accordance with the NIH Guide for the Care
and Use of Laboratory Animals. A Boston University Med-
ical Campus Institutional Animal Care and Use Commit-
tee approved protocol and National Institutes of
Health Guide for the Care and Use of laboratory Ani-
mals were followed.
Immunofluorescence
Hs578T and SUM149 cells were grown overnight on
glass cover slips. Upon harvest, cells were washed with
cold PBS, fixed with 4 % fresh paraformaldehyde for
10 minutes, permeabilized in 0.5 % Triton X-100 for
10 minutes, and blocked with 2 % BSA overnight. Cells
were incubated with anti-AHR antibody H-211 (Santa
Cruz Biotechnology, Dallas, TX) for 2 hours, washed in
PBS and incubated with Alexa Fluor® 594 conjugated
anti-rabbit IgG (Molecular Probes, Eugene, OR) for
60 minutes. Cover slips were washed and mounted on
slides with ProLong® Gold Antifade Reagent (Life Tech-
nologies, Carlsbad, CA). Photomicrography was performed
with a Nikon Deconvolution Wide-Field Epifluorescence
Microscope using NIS Elements software. No background
fluorescence was detectable in samples treated with the
secondary antibody alone.
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Immunohistochemistry
Immunohistochemistry was performed on slides of
paraffin-embedded, 5 μm-thick sections of breast invasive
ductal carcinoma in a tissue microarray (US Biomax, Inc.,
Rockvilla, MD) by standard protocol on an intelliPATH
Automated Slide Staining System from Biocare Medical
(Concord, CA). Briefly, the slides were heated for 15 mi-
nutes at 60 °C followed by deparaffinization starting with
xylene and rehydrated through graded alcohols to distilled
water. Antigen-retrieval was then performed using Diva
Decloaker (Biocare Medical) reagent at 100 °C for 35 mi-
nutes, and then at 85 °C for 10 minutes. Slides were incu-
bated with Biocare Medical Peroxidase 1 solution for
10 minutes at room temperature, washed with TBST,
blocked with Biocare Medical Background Sniper for
30 minutes and washed. Primary AHR-specific antibody
(clone H-211, 1:50 dilution, Santa Cruz Biotechnology)
was diluted in Biocare Medical Da Vinci Green Diluent
and incubated for 2 hours at room temperature followed
by washing in TBST. Incubation in Biocare Medical
Mach 4 Universal HRP Polymer was then performed
for 30 minutes followed by washing in TBST. DAB
was diluted in DAB substrate buffer and applied to slides
for 5 minutes followed by washing in deionized-H2O. A
light hematoxylin stain was applied, the slides were
dehydrated, air dried, and mounted, using EcoMount
and a coverslip. Microphotography was performed
with an Olympus Upright Microscope using QCapture
software. No background stain was detectable in the
absence of AHR-specific antibody.
Statistical analyses
Statistical analyses were performed with Prism (GraphPad
Software, La Jolla, CA) or StatPlus (Alexandria, VA) unless
otherwise noted. Data are presented as mean ± standard
error where applicable. One-way analysis of variants
(ANOVAs; simple) were used to determine significance.
For experiments measuring relative fold-changes in gene
expression (determined using the Pfaffl method [103] with
Gapdh mRNA used for normalization), statistical analyses
were performed using SAS v9.3. For comparisons of
fold-change in vehicle-treated ALDHhigh versus vehicle-
treated ALDHlow, and FICZ-treated ALDHlow versus
vehicle-treated ALDHlow cells, Gapdh-normalized expres-
sion levels were normalized to expression levels in vehicle-
treated ALDHlow cells. For comparisons of fold-change
with FICZ-treated ALDHhigh versus vehicle-treated
ALDHhigh cells, Gapdh-normalized expression levels were
normalized to expression levels in vehicle-treated ALDH-
high cells. Statistical significance was determined with
the Wilcoxon rank sum test. Statistical analyses of the
mouse model compared the average rate of change over
time between groups using a random effects model with a
random intercept for each mouse. Day 22 was used as the
starting (baseline) value to calculate the rate of change. All
mouse analyses were performed using SAS v9.3 using a
0.05 level of significance.
Availability of supporting data
The data sets supporting the results of this article are
included within the article and its additional files
(Additional file 7, excel document). For further informa-
tion, please contact the corresponding author.
Additional files
Additional file 1: Additional Figure S1. Nuclear AHR staining in triple
negative breast cancer cell lines and primary breast cancers. (A) AHR
immunofluorescence staining in SUM149 (left) and Hs578T (right) triple
negative breast cancer cell lines are shown (Top: bright field in black
and white; Bottom: Alexafluor fluorescence in black and white). (B) AHR-
specific staining in tissue from two representative human breast cancers
from a total of 50 samples is shown (Top: normal breast control, Middle:
Her 2+, invasive ductal carcinoma; Bottom: ER−/PR−/Her2− invasive
ductal carcinoma). (PDF 10468 kb)
Additional file 2: Additional Figure S2. AHR modulation alters ALDH
activity in ER−, immortalized MCF-10 F epithelial cells. (A) Representative flow
cytometry dot plots of ALDEFLUOR™ staining of MCF10F cells treated for
48 hours with vehicle, 10 μM CH223191, or 0.5 μM FICZ. Regions representing
ALDHhigh cells were drawn based on the signal generated in the presence
of DEAB. (B) MCF-10 F cells were treated as in (A) and assayed for
the percentage of ALDHhigh cells. Data from four experiments were
normalized to results obtained with naive cells (mean baseline = 0.2 %
ALDHhigh cells) and presented as mean fold-change from naive ± standard
error. Asterisks indicate a significant decrease in the percentage of ALDHhigh
cells, *P <0.05, **P <0.005. A cross indicates a significant increase in ALDHhigh
cells, +P <0.05. (PDF 97 kb)
Additional file 3: Additional Figure S3. Limited plasticity of SUM149
with regard to ALDH expression. SUM149 cells were sorted into ALDHhigh and
ALDHlow populations and treated for 96 hours with vehicle or 1 μM CH223191.
Every 24 hours, cells were assayed for the percent of (A) ALDHhigh and (B)
ALDHlow cells to determine how quickly cells revert to the baseline ALDHhigh
and ALDHlow levels. Data are presented as the means from 3 (72 and 96 hours)
or 4 (0, 24 and 48 hours) experiments ± standard errors. (PDF 48 kb)
Additional file 4: Additional Figure S4. AHR agonists accelerate
migration of SUM149 cells. (A) Representative images of cell migration at
24 and 48 hours after SUM149 cells were sorted into the ALDHhigh
population, cultured to confluence, scratched, and treated with vehicle,
0.5 μM FICZ or 1 nM TCDD. Data are representative of five independent
experiments. Black lines indicate the borders of the original scratch. (B)
ALDHhigh SUM149 cells were treated as in (A) and the percent exposed
area was quantified at 24 and 48 hours. Data from five experiments were
normalized to results obtained with naive cells and presented as the
mean percent exposed area ± standard error. Asterisks indicate a
significant decrease in exposed area, *P <0.05, **P <0.01. (PDF 6744 kb)
Additional file 5: Additional Figure S5. Ahr and Cyp1b1 expression
correlate with expression of stem cell- and migration/invasion-
associated genes in the CCLE database. The gene set enrichment
analysis (GSEA) tool (http://www.broad.mit.edu/gsea) was used to rank
genes from the cancer cell line encyclopedia (CCLE) dataset [66] based on
the correlation of their expression profiles with (A) Ahr and (B) Cyp1b1
expression. Considering stem cell- and migration/invasion-associated
genes present in the CCLE microarray data, their position in the
ranked list (represented with vertical black lines in the panels)
incremented the enrichment score statistic (ES, plotted in green). A
significant positive correlation between Ahr or Cyp1b1 and the gene
set was demonstrated by GSEA (P = 0.025 and 0.021, respectively),
with Msi1 showing the lowest correlation value in both analyses.
(PDF 99 kb)
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Additional file 6: Additional Figure S6. Ahr and Cyp1b1 expression
correlate with expression of stem cell- and migration/invasion-associated
genes in the TCGA database. Expression of genes from the cancer
genome atlas (TCGA) dataset [68] were ranked based on the correlation
of their expression profiles with Ahr (A) and Cyp1b1 (B) expression. The
enrichment score (in green) was computed by considering the position
of the stem cell- and migration/invasion-associated genes in the ranked
list obtained from the TCGA RNA-Seq data. A significant positive correlation
between expression of the putative AHR target genes and Ahr or
Cyp1b1 expression (P = 0.047, P = 0.0001, respectively) was demonstrated.
The ranking of Msi1 demonstrated a low correlation with both Ahr and
Cyp1b1 expression. (PDF 100 kb)
Additional file 7: The data sets supporting the results of each of the
figures in this article are included within this excel document. For further
information, please contact the corresponding author. (XLSX 81 kb)
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